Insulin recalled due to potential missing label

Mylan Pharmaceuticals Inc. is recalling one batch of insulin glargine injection (Semglee; 100 units/mL in 3-mL prefilled pens) due to the potential for a missing label on some pens within a labeled carton, the FDA announced on Jan. 19.

No related adverse events have been reported to the company to date. The recalled lot was distributed in the U.S. between May 11 and Nov. 11, 2021. This recall does not pertain to the recently launched interchangeable biosimilars, insulin glargine-yfgn injection, branded as Semglee, or insulin glargine-yfgn injection, an unbranded product.